A protease biosensor and its application in protease detection and inhibitor screening
By constructing a BRET-based protease biosensor, which combines protease recognition with cleavage of short peptides, the sensitivity and specificity issues in protease detection and inhibitor screening were resolved, achieving efficient protease detection and drug screening.
Patent Information
- Application Number
- CN202210882903.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-07-26
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2042-07-26
AI Technical Summary
Existing protease detection methods lack sufficient sensitivity and specificity, and the screening process for protease drug inhibitors is complex, making it difficult to achieve high-throughput applications.
A protease biosensor was constructed, utilizing bioluminescent resonance energy transfer (BRET) technology. Through gene fusion expression, luciferase and fluorescent protein were used as donor and acceptor, respectively. The protease then recognized and cleaved short peptides, achieving highly sensitive and specific detection and screening.
It achieves high sensitivity and specificity for the detection of proteases, with a detection limit at the pM level, significantly improved dynamic range, simplified operation process, reduced background interference signals, and is suitable for high-throughput screening of protease inhibitors.
Smart Images

Figure CN115850504B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biosensors, specifically relating to a protease biosensor and its application in protease detection and inhibitor screening. Background Technology
[0002] Plasmin, belonging to the serine protease family, is a proteolytic enzyme in the human body involved in the regulation of the fibrinolytic and coagulation systems. Plasmin and its inhibitors often work in concert, playing crucial roles in various biological and physiological processes, including tissue proliferation, wound healing, ovulation and fertilization, cell adhesion, migration, differentiation, apoptosis, pathogen invasion, tumor invasion, and metastasis. Furthermore, plasmin is associated with numerous diseases such as radiation-induced trauma, cardiovascular disease, pulmonary embolism, cancer, Alzheimer's disease, AIDS, and severe respiratory infections such as COVID-19. Therefore, plasmin detection and the screening of its drug inhibitors are of great significance in the in vitro diagnosis and clinical treatment guidance of major diseases.
[0003] Traditional methods for detecting proteases include ultraviolet spectrophotometry, colorimetry, immunoassay, fluorescence assay, radiolabeling, high-performance liquid chromatography (HPLC), and mass spectrometry. However, ultraviolet spectrophotometry and colorimetry suffer from poor sensitivity and repeatability; immunoassays rely on expensive antibodies, hindering high-throughput applications; and fluorescence and radiolabeling methods require labeling the enzyme or substrate and repeated washing, resulting in complex procedures. Recent commercial kits for detecting plasmin based on fluorescent small-molecule AMC-modified substrates offer high sensitivity, but their high cost makes the detection process too expensive. HPLC and mass spectrometry suffer from low sensitivity and high analytical costs. Unconventional methods, such as biosensors and electrochemical sensors based on novel magnetic nanomaterials, nanorods, and electrochemical materials, require specific modification of the target analyte and involve multi-step chemical coupling and repeated washing and purification processes.
[0004] Bioluminescent resonance energy transfer (BRET) is a non-radiative energy transfer process where, based on the enzyme-mediated energy transfer of luciferase, the emission frequency from the excited state to the ground state overlaps with the absorption frequency of the fluorophore of the acceptor protein, and the spatial distance between the donor and acceptor is less than 10 nm. This energy transfer induces a fluorescence signal in the acceptor protein. This method, as a highly efficient optical "molecular scale," is widely used in protein-protein interaction studies. Its advantages include no need for an external excitation source, low background signal, no need for repeated washing, simple operation, and the ability to perform in vivo optical imaging studies.
[0005] Protease inhibitors mainly include endogenous inhibitors, synthetic peptides, and natural products. With the tremendous development of biomedicine and organic chemistry, the screening of drug inhibitor libraries targeting proteases has become increasingly demanding. Computer-aided drug design and structure-based virtual screening have greatly advanced new drug development, but have also presented new challenges to detection and screening technologies. Therefore, developing highly sensitive and specific protease detection and high-throughput screening technologies for protease inhibitors is crucial not only for guiding the early diagnosis and treatment of major diseases but also for providing essential foundational support for new drug development. Summary of the Invention
[0006] This invention aims to at least solve one of the technical problems existing in the prior art. To this end, this invention proposes a method for constructing a protease biosensor and its inhibitor screening application. The protease biosensor constructed in this invention can qualitatively or quantitatively detect proteases in samples with high specificity and high detection sensitivity. Furthermore, detection does not require an external excitation light source; it is powered solely by bioluminescence, greatly reducing background interference signals from the emitted light source.
[0007] In a first aspect, the present invention provides a biosensor comprising a bioluminescent resonance energy transfer donor, a protease-recognized cleaved peptide, and a bioluminescent resonance energy transfer acceptor; wherein the protease-recognized cleaved peptide is linked to the bioluminescent resonance energy transfer donor and the bioluminescent resonance energy transfer acceptor in the biosensor via a linker fragment.
[0008] In some embodiments of the present invention, the linker segment is hydrophobic and has an extended flexible linker.
[0009] In some embodiments of the present invention, the linker fragment includes at least one of (GGS)n, (GS)n, (GGGS)n, and (GGGGS)n. Of course, those skilled in the art can select other linker fragments, including but not limited to (GGS)n, (GS)n, (GGGS)n, and (GGGGS)n, according to actual usage requirements.
[0010] In some embodiments of the present invention, the bioluminescent resonant energy transfer donor includes luciferase, a functional fragment of luciferase, or a bioactive variant thereof.
[0011] Of course, it's important to understand that the BRET donor can actually be any bioluminescent protein, not just luciferase. It only needs to function as an agent for a suitable substrate, catalyzing a chemical reaction to emit visible light. Essentially, it releases energy in the form of light without generating heat or other energy transfer mechanisms. In this field, common bioluminescent proteins are generally isolated from bioluminescent organisms, mostly marine, with a smaller proportion being terrestrial bioluminescent organisms, such as bacteria, protozoa, insects and their larvae, coelenterates, annelids, mollusks, spiders, myriapods, fish, fungi, and crustaceans.
[0012] In some embodiments of the present invention, the luciferase includes NanoLuc luciferase, firefly luciferase, renal luciferase, coelenterate luciferase, North American blue firefly luciferase, click beetle luciferase, bacterial luciferase, jellyfish luciferase, Gaussia luciferase, Daphnia gracilis luciferase, and apple fly maggot luciferase. Of course, those skilled in the art can select other luciferases according to actual usage requirements, including but not limited to NanoLuc luciferase, firefly luciferase, renal luciferase, coelenterate luciferase, North American blue firefly luciferase, click beetle luciferase, bacterial luciferase, jellyfish luciferase, Gaussia luciferase, Daphnia gracilis luciferase, and apple fly maggot luciferase.
[0013] In this invention, the term "BRET receptor" refers to a fluorescent substance having a fluorescent luminescent domain or functional group.
[0014] In some embodiments of the present invention, the bioluminescent resonance energy transfer acceptor includes at least one of fluorescent proteins, small molecule fluorescent dyes, fluorescent nanomaterials, fluorescent microspheres, and substances labeled with at least one of the above-mentioned fluorescent proteins, small molecule fluorescent dyes, fluorescent nanomaterials, and fluorescent microspheres.
[0015] In some embodiments of the present invention, the fluorescent protein includes mNeonGreen, Clover series green fluorescent proteins, GFP, BFP, CFP, YFP, EGFP, Venus, mOrange, Topaz, DsRed, mTFP1, mRFP1, mCherry, TagRFP, TurBoFB, or functional fragments or bioactive variants of any of these. Of course, those skilled in the art can select other fluorescent proteins according to actual application needs, including but not limited to mNeonGreen, Clover series green fluorescent proteins, GFP, BFP, CFP, YFP, EGFP, Venus, mOrange, Topaz, DsRed, mTFP1, mRFP1, mCherry, TagRFP, and TurBoFB.
[0016] In this embodiment of the invention, the inventors used gene fusion expression to select a BRET donor and acceptor pair with excellent optical properties. They introduced a luciferase gene, a fluorescent protein gene, and a linker gene of different lengths with flexibility and hydrophobicity between the two genes. After gene fusion and expression, the luciferase and fluorescent protein can swing freely in three-dimensional space under the action of the flexible linker, which greatly increases the collision probability of the BRET donor and acceptor and improves the bioluminescent resonance energy transfer efficiency, thereby obtaining a stable bioluminescent resonance energy transfer sensor.
[0017] According to a second aspect of the invention, in some embodiments of the invention, the protease recognizes and cleaves short peptides that can specifically bind to the protease and be cleaved by the protease.
[0018] In some embodiments of the present invention, the proteases include plasminogen activator, thrombin, apoptotic proteases, matrix metalloproteinases, trypsin, chymotrypsin, coronavirus main protease, and capsid protease. Among them, apoptotic proteases include apoptotic protease 3, apoptotic protease 8, and apoptotic protease 9. Matrix metalloproteinases include matrix metalloproteinase 2 and matrix metalloproteinase 9. Of course, those skilled in the art can select other proteases according to actual usage needs, including but not limited to the above-mentioned plasminogen activator, thrombin, apoptotic proteases, matrix metalloproteinases, trypsin, chymotrypsin, coronavirus main protease, and capsid protease.
[0019] Of course, those skilled in the art can choose other recognition cleavage peptides for the detection of specific substances according to actual needs, including but not limited to the protease recognition cleavage peptides mentioned above.
[0020] In this embodiment of the invention, based on the bioluminescent resonance energy transfer sensor described in the first aspect of the invention, the inventors employed gene fusion expression to carry a specific protease recognition site element into the linker gene, thus obtaining a bioluminescent resonance energy transfer sensor capable of targeting specific proteases. This sensor effectively achieves rapid detection of multiple proteases with high sensitivity and high specificity by using a high-brightness bioluciferase and a fluorescent protein with high fluorescence intensity matching its spectral performance as the BRET donor and acceptor pair.
[0021] In some embodiments of the present invention, short peptides specifically recognized by different proteases are introduced between two flexible linkers. When the protease is absent, the bioluminescent resonance energy transfer efficiency is maximized in the presence of a luciferase substrate. Upon addition of the protease, as the protease concentration gradually increases, the short peptide is specifically recognized and hydrolyzed by the protease, thereby gradually reducing the bioluminescent resonance energy transfer efficiency, weakening the resonance fluorescence signal intensity, until no energy transfer occurs and saturation is achieved. By reading this change in fluorescence signal, highly sensitive and specific qualitative or quantitative detection of specific proteases can be achieved.
[0022] In some embodiments of the present invention, the amino acid sequence of the protease-specifically recognized cleaved short peptide is KKYKVKE. This protease-specifically recognized cleaved short peptide is a plasmin-specifically recognized cleaved short peptide, meaning that when plasmin is present in the system, the plasmin will recognize the short peptide and cleave its peptide segment. In some embodiments of the present invention, the luciferase substrate includes coelin and its derivatives. Coelin is a class of imidazopyrazinone luminescent substrates, including but not limited to coelin 400a, furimazine, natural coelin, coelin h, coelin cp, coelin f, coelin hcp, coelin n, coelin e, etc.
[0023] In some embodiments of the present invention, depending on the selection of luciferase, the generation of luciferase bioluminescence also requires a cofactor, which includes, but is not limited to, ATP, oxygen, calcium ions, magnesium ions, etc., or any combination of two or more of them.
[0024] In some embodiments of the present invention, the fluorescence signal collection device includes, but is not limited to, a multifunctional microplate reader. When using a multifunctional microplate reader to collect fluorescence signals, its filtering method can be a continuously adjustable wavelength grating, a fixed wavelength filter, or a combination of multiple fused optical paths, and the corresponding parameter settings need to be optimized and adjusted as needed.
[0025] A second aspect of the present invention provides a method for preparing a biosensor, comprising the following steps:
[0026] (1) The functional units of the biosensor according to any one of claims 1 to 7 are recombined and linked in the expression vector according to the connection order of the functional units; the functional units include a bioluminescent resonance energy transfer donor, a linker fragment, a bioluminescent resonance energy transfer receptor, and a protease-recognized cleaved short peptide.
[0027] (2) Screen positive clones, extract plasmids, transform them into competent cells and induce protein expression.
[0028] (3) Break the cells and extract the crude protein, which is the biosensor.
[0029] In some embodiments of the present invention, the method for preparing the biosensor specifically includes:
[0030] (1) The functional units in the biosensor of the first aspect of the present invention are recombined and linked in a carrier cell according to the connection order of the functional units; the functional units include a bioluminescent resonance energy transfer donor, a linker fragment, a bioluminescent resonance energy transfer receptor, and a protease-recognized cleavage short peptide.
[0031] (2) Screen positive clones, extract plasmids, transform them into competent E. coli cells and induce efficient protein expression.
[0032] (3) The crude protein solution was extracted from the cells and then purified through various separation and purification methods to obtain the biosensor.
[0033] In some embodiments of the present invention, the nucleotide sequence of the biosensor obtained by recombinantly linking the amino acid sequences of the following functional groups, such as SEQ ID NO:1 (mNeonGreen), SEQ ID NO:2 (NanoLuc), SEQ ID NO:3 (Linker) and SEQ ID NO:4 (fibrinolytic enzyme recognition cleavage short peptide), is shown in SEQ ID NO.5.
[0034] Of course, those skilled in the art can add other modifying sequences, such as tag sequences, without affecting its function, to achieve purposes such as immobilization, screening, quantification, or tracing. The modifying sequences include, but are not limited to, His6 histidine tags and resistance tags.
[0035] In some embodiments of the present invention, the connection method of each functional unit includes, but is not limited to, recombination ligation based on PCR amplification.
[0036] In some embodiments of the present invention, screening of positive clones is based on kanamycin LB plates. Of course, depending on actual needs, plates corresponding to other antibiotic resistance tags can also be used for screening. The positive clones obtained through screening can be further validated or screened using sequencing after plasmid extraction.
[0037] In some embodiments of the present invention, isopropyl-β-D-thiogalactoside is used as the expression inducer. Of course, other suitable expression inducers can also be used to induce the expression of the biosensor according to actual needs.
[0038] According to a second aspect of the invention, in some embodiments of the invention, step (3) further includes column separation and purification after cell disruption.
[0039] In some embodiments of the present invention, insoluble proteins and cell debris may be removed by means of centrifugation before column separation.
[0040] In some embodiments of this invention, separation and purification are performed using Akta Pure and HisTrap Excel columns. After separation on the HisTrap Excel column, proteins are eluted, and then a PD-10 desalting column is used to remove imidazoles, salts, and other small molecules to further purify the biosensor (the obtained biosensor purity can reach 95%). Of course, other suitable separation and purification methods can also be used to obtain high-purity biosensors according to actual application requirements.
[0041] In some embodiments of the present invention, the expression vector of the biosensor includes, but is not limited to, Escherichia coli, yeast, or specific cell secretion expression or insect expression methods.
[0042] A third aspect of the present invention provides the application of the biosensor described in the second aspect of the present invention in any one of the following (1) to (3);
[0043] (1) Qualitative or quantitative detection of protease;
[0044] (2) Screening of protease inhibitors or target substances;
[0045] (3) Quantitative comparison of the activity of protease inhibitors or target substances or effect evaluation.
[0046] In some embodiments of this invention, the biosensor prepared by the inventors uses plasmin as the target protein. When the plasmin in the system does not reach the detection limit or is absent, bioluminescent energy is completely transferred under the action of a luciferase substrate. However, when the plasmin reaches or exceeds the detection limit, bioluminescent energy is partially transferred or not transferred at all under the action of a luciferase substrate. By reading these changes in fluorescence signal, highly sensitive and specific qualitative or quantitative detection of specific proteases can be achieved.
[0047] Plasmin, belonging to the serine protease family, is a proteolytic enzyme in the human body involved in the regulation of the fibrinolytic and coagulation systems. Plasmin and its inhibitors often work in concert, playing crucial roles in various biological and physiological processes, including tissue proliferation, wound healing, ovulation and fertilization, cell adhesion, migration, differentiation, apoptosis, pathogen invasion, tumor invasion, and metastasis. Furthermore, plasmin is associated with numerous diseases such as radiation-induced trauma, cardiovascular disease, pulmonary embolism, cancer, Alzheimer's disease, AIDS, and severe respiratory infections such as COVID-19. Therefore, plasmin detection and the screening of its drug inhibitors are of great significance in the in vitro diagnosis and clinical treatment guidance of major diseases.
[0048] In some embodiments of the present invention, the biosensor can also specifically screen different protease target drugs or protease inhibitors, such as small molecule compounds or protein complexes. When the protease concentration in the system is fixed at a certain threshold, under the action of a luciferase substrate, bioluminescence energy undergoes partial or no transfer. However, with the addition of protease inhibitors or target drugs, protease activity is inhibited, preventing short peptides from being effectively recognized and cleaved by the protease. At this time, the bioluminescence resonance energy transfer efficiency gradually increases, and by collecting changes in fluorescence signals, highly efficient target drugs or inhibitors targeting specific proteases can be screened.
[0049] In some embodiments of the present invention, the protease concentration threshold can be optimized based on the amount of biosensor and protease used in the system.
[0050] In some embodiments of the present invention, after the target analyte or its inhibitor is added to the detection system, it should be incubated for a period of at least 10 minutes. In some embodiments of the present invention, the incubation time is 30 minutes.
[0051] In some implementations, the maximum dynamic range of the detection is 30 minutes when the sensor and plasmin are incubated together. This dynamic range varies with the length of the incubation time and increases with the duration of incubation.
[0052] In some implementations, the multifunctional microplate reader collects fluorescence signals. The filtering method of the reader can be a continuously adjustable wavelength grating, a fixed wavelength filter, or a combination of multiple fused optical paths. The corresponding parameter settings need to be optimized and adjusted as needed.
[0053] Of course, those skilled in the art can, based on the design principles of this invention, adjust the introduced recognition cleavage short peptide to other specific substances, so that the biosensor of this invention can detect other substances. The target detection substances include, but are not limited to, proteases, proteins, antigens, antibodies, nucleic acids, bacteria, viruses or heavy metals, or any combination thereof.
[0054] The beneficial effects of this invention are:
[0055] 1. This invention provides a stable bioluminescent resonance energy transfer sensor, which shortens the spatial distance of the BRET donor / acceptor pair by gene fusion expression and the introduction of a flexible linker, thereby improving the bioluminescent resonance energy transfer efficiency and enabling the sensor's bioluminescent resonance energy transfer efficiency (BRET ratio) to be higher than 3.0.
[0056] 2. This invention provides a highly sensitive and specific protease bioluminescent resonance energy transfer sensor. This sensor incorporates a protease-specific recognition and cleavage short peptide, enabling protease-specific recognition and cleavage simultaneously with optical signal energy transfer. This alters the energy transfer efficiency (improving the BRET dynamic range and significantly reducing EC compared to traditional sensors). 50 The system enables the detection of various proteases within a detection range of 10-100 pM, with a detection limit (LOD) reaching the pM level (0.732 pM) and a half-maximal effective concentration (EC50) of 0.241 nM. The plasmin BRET biosensor constructed based on this technology exhibits high specificity, specifically high specificity only for plasmin, while showing lower specificity for other proteases. Its maximum dynamic range is 440.7 ± 14.3%, representing a significant improvement over the existing BRET6 detection technology.
[0057] 3. The apparent affinity constant (K) of the plasmin BRET biosensor in this invention. d,app The concentration is 0.225 nM, which has an extremely high affinity for plasmin.
[0058] 4. This invention provides a method for constructing a bioluminescent resonance energy transfer sensor. This method offers excellent and controllable performance, is simple to operate, easy to use, and requires no repeated washing; detection can be completed simply by adding samples and incubating. Furthermore, by introducing different protease-specific recognition cleavage sites, it achieves different protease detection purposes. Moreover, detection requires no external excitation light source, relying solely on bioluminescence for energy, significantly reducing background interference signals from emitted light sources.
[0059] 5. The biosensor in this invention can be effectively applied to the screening of drugs and target substances. By changing the energy transfer efficiency, the half-inhibition concentration (IC50) can be calculated, thereby achieving rapid and effective high-throughput screening. It is simple to operate and easy to repeat. It has excellent screening effects for endogenous inhibitors such as anti-plasmin, aprotinin, and leupeptin. Attached Figure Description
[0060] Figure 1 This is a schematic diagram of the composition of the bioluminescent resonant energy transfer sensor in Example 1.
[0061] Figure 2 The figures show the energy transfer efficiency curves of the bioluminescent resonant energy transfer sensor in Example 1 under different conditions.
[0062] Figure 3 The graphs (a) and bar charts (b) show the detection results of different proteases at 10 nM using the bioluminescent resonance energy transfer sensor in Example 1.
[0063] Figure 4 The graph shows the detection results of different proteases at 10 nM for BLI kinetics.
[0064] Figure 5 The graphs and bar charts show the detection results of different concentrations of different proteases by the bioluminescent resonant energy transfer sensor in Example 1.
[0065] Figure 6 The following is an evaluation of the effect of the bioluminescent resonance energy transfer sensor in Example 1 on the detection of plasmin at different incubation times. In this example, a is a spectral phenomenon diagram of the plasmin BRET biosensor at different incubation times, and b is an evaluation of the energy transfer efficiency of the plasmin BRET biosensor at different incubation times.
[0066] Figure 7 The bioluminescent resonance energy transfer sensor in Example 1 is shown to detect plasmin in PBS buffer. In this example, a represents the detection spectrum of the plasmin BRET biosensor; b represents the half-maximal effect concentration (EC50). 50Nonlinear fitting curve; c is the working concentration standard curve; d is the apparent affinity nonlinear fitting curve; e is the corresponding BLI inhibition kinetic curve.
[0067] Figure 8 The effect of the bioluminescent resonance energy transfer sensor in Example 1 on the detection of plasmin in plasma is shown, where a is the half-maximal effect concentration (EC50). 50 a) Nonlinear fitting curve; b) Working concentration standard curve; c) Apparent affinity nonlinear fitting curve.
[0068] Figure 9 The nonlinear fitting curve (a) of the IC50 half-inhibition concentration of anti-plasmin and the corresponding BLI inhibition kinetic curve (b) of the bioluminescent resonant energy transfer sensor in Example 1 are shown.
[0069] Figure 10 The nonlinear fitting curve (a) of the IC50 of the half-inhibitory concentration of aprotinin by the bioluminescent resonance energy transfer sensor in Example 1 and the corresponding BLI inhibition kinetic curve (b) are shown.
[0070] Figure 11 The nonlinear fitting curve (a) of the IC50 of the half-inhibitory concentration of leupeptin by the bioluminescent resonance energy transfer sensor in Example 1 and the corresponding BLI inhibition kinetic curve (b) are shown. Detailed Implementation
[0071] To make the objectives, technical solutions, and effects of this invention clearer, the invention will be further described in detail below with reference to specific embodiments. It should be understood that the specific embodiments described in this specification are merely for explaining the invention and are not intended to limit the invention.
[0072] Unless otherwise specified, all experimental materials and reagents used are commercially available consumables and reagents.
[0073] Example 1: A plasminogen activator biosensor
[0074] (1) Fabrication of biosensors:
[0075] In this embodiment of the invention, the constructed biosensor is a bioluminescent resonant energy transfer sensor, and its specific structure is as follows: Figure 3 As shown, the functional elements of this biosensor include a bioluminescent resonance energy transfer (BRET) donor, a BRET acceptor, a linker fragment connecting the BRET donor and acceptor, and a plasmin-recognized cleavage peptide KKYKVKE (SEQ ID NO:4).
[0076] In this embodiment of the invention, the BRET donor is luciferase NanoLuc, the BRET acceptor is green fluorescent protein mNeonGreen, and the linker fragment is flexible long hydrophobic linker (GGS)n.
[0077] Structural diagram as follows Figure 1 As shown.
[0078] The amino acid sequence of mNeonGreen is as follows:
[0079] MVSKGEEDNMASLPATHELHIFGSINGVDFDMVGQGTGNPNDGYEELNLKSTKGDLQFSPWILVPHIGYGFHQYLPYPDGMSPFQAAMVDGSGYQVHRTMQFEDGASLTVNYRYTYEGSH IKGEAQVKGTGFPADGPVMTNSLTAADWCRSKKTYPNDKTIISTFKWSYTTGNGKRYRSTARTTYTFAKPMAANYLKNQPMYVFRKTELKHSKTELNFKEWQKAFTDVMGMDELYK(SEQ ID NO: 1).
[0080] The amino acid sequence of NanoLuc is as follows:
[0081] MVFTLEDFVGDWRQTAGYNLDQVLEQGGVSSLFQNLGVSVTPIQRIVLSGENGLKIDIHVIIPYEGLSGDQMGQIEKIFKVVYPVDDHHFKVILHYGTLVIDGVTPNMIDYFGRPYEGIAVFDGKKITVTGTLWNGNKIIDERLINPDGSLLFRVTINGVTGWRLCERILA (SEQ ID NO: 2).
[0082] The amino acid sequence of the linker fragment is as follows:
[0083] GGGSGGGSGGGSGGGSGGGSGGGS (SEQ ID NO: 3).
[0084] The specific preparation method is as follows:
[0085] A His6 histidine tag and an SH3 domain were linked to the N-terminus of the mNeonGreen gene. A hydrophobic and somewhat extensible flexible peptide chain (GGS)n, a Plasmin-recognized cleavage peptide, another hydrophobic and somewhat extensible flexible peptide chain (GGS)n, and the NanoLuc gene were linked to the C-terminus of the mNeonGreen gene. These gene fragments were recombined using PCR amplification and then ligated into a linearized *E. coli* expression vector at 37°C for 30 min using a one-step cloning method. The resulting cells were then transformed into DH5α competent cells after heat treatment at 42°C. After recovery by shaking culture at 37°C, the cells were plated onto LB agar plates containing kanamycin for screening. Single colonies were selected for colony PCR and double enzyme digestion identification. Colonies were then expanded in liquid LB medium (containing kanamycin) and plasmids were extracted. Positive clones were identified by sequencing with Shanghai Sangon Biotech that showed 100% agreement with the target sequence.
[0086] The target sequence is:
[0087] MVSKGEEDNMASLPATHELHIFGSINGVDFDMVGQGTGNPNDGYEELNLKSTKGDLQFSPWILVPHIGYGFHQYLPYPDGMSPFQAAMVDGSGYQVHRTMQFEDGASLTVNYR YTYEGSHIKGEAQVKGTGFPADGPVMTNSLTAADWCRSKKTYPNDKTIISTFKWSYTTGNGKRYRSTARTTYTFAKPMAANYLKNQPMYVFRKTELKHSKTELNFKEWQKAFTD VMGMDELYKGGSGGSGGSGGSGGSGGSKKYKVKEGGSGGSGGSGGSGGSGGSMVFTLEDFVGDWRQTAGYNLDQVLEQGGVSSLFQNLGVSVTPIQRIVLSGENGLKIDIHVI IPYEGLSGDQMGQIEKIFKVVYPVDDHHFKVILHYGTLVIDGVTPNMIDYFGRPYEGIAVFDGKKITVTGTLWNGNKIIDERLINPDGSLLFRVTINGVTGWRLCERILA(SEQ ID NO:5).
[0088] The plasmids that were correctly identified by sequencing were heat-treated at 42°C and transformed into BL21(DE3) competent cells. After recovery by shaking culture at 37°C, the cells were plated onto LB plates containing kanamycin for screening. Single colonies were selected as E. coli expression strains. The plasmids were extracted by amplification culture in liquid LB medium (containing kanamycin) at 37°C and 200 rpm. The cells were then cryopreserved at -80°C for future use.
[0089] Frozen glycerol bacterial culture was inoculated into LB liquid medium containing kanamycin and cultured overnight at 37°C and 200 rpm to activate the strain. Then, the activated bacterial culture was inoculated at 2% into fresh LB liquid medium containing kanamycin and cultured until the OD600 of the bacterial culture reached 0.4-0.6, which is the logarithmic growth phase of the strain. Then, 0.2 mM isopropyl-β-D-thiogalactoside inducer was added and the gene was induced to express rapidly for 24 h at 16°C and 180 rpm.
[0090] After expression, the bacterial cells were collected by centrifugation at 8000 rpm for 15 min at 4℃, and the supernatant LB medium was discarded. A certain amount of binding buffer (20 mM Tris-HCl, 150 mM sodium chloride, 20 mM imidazole) was added to suspend the bacterial cells. The cells were then homogenized by high pressure homogenizer and centrifuged at 20000 rpm for 30 min at 4℃ to separate and remove insoluble proteins and cell debris, and obtain the supernatant soluble crude protein solution. The target protein was separated and purified using Akta Pure and HisTrap Excel columns. The HisTrap Excel column removes contaminating proteins by specifically binding to the histidine-tagged fusion protein with the nickel packing material. Then, the high concentration of imidazole competitively binds to the nickel packing material through a linear gradient elution buffer (20 mM Tris-HCl, 150 mM sodium chloride, 500 mM imidazole), gradually eluting the histidine fusion protein from the column. The obtained protein is then desalted using a PD-10 desalting column to remove imidazole, salts, and other small molecules, yielding the purified target protein (i.e., the biosensor). After protein electrophoresis identification, the protein is aliquoted, flash-frozen in liquid nitrogen, and stored at -80°C for later use.
[0091] (2) Biosensor performance evaluation:
[0092] The biosensor prepared in this embodiment was used to determine its spectroscopic performance using a multifunctional microplate reader. The specific procedure was as follows: A 96-well non-adsorbed white opaque plate was used to prepare a reaction system. The reaction system included 1 nM of the biosensor and 10 nM of different proteases (plasmin, fibrinogen, thrombin, coagulation factor Xa (or factor Xa protease), and urokinase) added sequentially. The plate was incubated at room temperature with shaking for 30 min. Then, 25 μM of enterolumin 400a substrate was added (the remainder was made up with PBS phosphate buffer (pH 7.4)), resulting in a total reaction volume of 100 μL. Fluorescence signal detection was performed immediately after adding the enterolumin 400a substrate. The microplate reader parameters were set to a scan range of 400-600 nm, a step size of 1 nm, and a gain of 100. BRET energy transfer efficiency was evaluated using a ratio method, which is calculated by dividing the fluorescence intensity of the receptor fluorescent protein at 500-550 nm by the fluorescence intensity of the donor luciferase at 415-465 nm.
[0093] The results are as follows Figure 2 As shown.
[0094] It can be observed that the energy transfer efficiency (BRET ratio) of the biosensor in Example 1 can be greater than 3.0.
[0095] To further analyze the detection kinetics, Fortebio octet biofilm layer optical interferometry (BLI) was used for detection. The specific steps were as follows: a commercially available NTA sensor (purchased from Satorius) was used to specifically identify the His6 histidine tag in the biosensor prepared in this embodiment, and unbound substances were washed away. Then, different protease solutions (10 nM) were used as target analytes for binding, and the kinetic changes were monitored in real time.
[0096] The results are as follows Figures 3-4 As shown.
[0097] It can be observed that the biosensor in Example 1 exhibits very strong specific binding to plasmin. Under the specific recognition and cleavage action of 10 nM plasmin, the energy transfer efficiency can be reduced by 81.8%, while the biosensor shows weaker specific recognition of other proteases. Specifically, the energy transfer efficiency of thrombin decreased by only 7.2%, coagulation factor Xa by only 22.0%, and urokinase by only 9.6%, while fibrinogen remained unchanged. This indicates that the biosensor in Example 1 does not have specific binding ability (or has low specific binding ability) for other proteases. BLI detection results ( Figure 4 The results were consistent with the above detection results, indicating that the biosensor has good specificity only for plasminogen activator, thus demonstrating that the biosensor in the above embodiments can be used for the specific detection of plasminogen activator.
[0098] To fully demonstrate the validity of the above results, the inventors used the same detection method as in the above embodiments to detect different concentrations (0, 1, 10, and 100 nM) of different proteases. The remaining volume of the system can be PBS phosphate buffer or PBS phosphate buffer containing 0.1% human plasma.
[0099] The results are as follows Figure 5 As shown.
[0100] It can be observed that even if the concentration of the protease changes significantly, the biosensor is not affected, indicating that the biosensor in the above embodiments has good anti-interference ability and can accurately detect fibrinolytic protease.
[0101] The inventors used the same detection method as described above to test the detection effect of the biosensor in the above embodiments based on different incubation times. The plasmin concentration was set to 10 nM, the temperature was room temperature, and the incubation times were 0, 5, 10, 20, 30, 45, 60, and 120 min, respectively.
[0102] The results are as follows Figure 6 As shown.
[0103] It was observed that the dynamic range of the BRET ratio changed significantly after 10 minutes of incubation. It stabilized between 10 and 30 minutes, but after 45 minutes, the dynamic range began to decline, indicating that the detection dynamic range gradually increases with prolonged incubation time. Furthermore, based on this result, it was found that a rapid detection time of at least 10 minutes is required to achieve a sufficient BRET dynamic range for effective detection of plasmin. Simultaneously, combined with… Figure 2The results show that, with an incubation time of 30 min, the maximum dynamic range of 10 nM plasmin detection is 440.7 ± 14.3%, which is about 6.3 times higher than the existing BRET6 detection technology (with a maximum dynamic range of about 70%).
[0104] Meanwhile, to evaluate the detection sensitivity of the aforementioned biosensor for plasminogen activator, the inventors used plasminogen activator standard solutions of 0–100 pM as detection samples, performed detection using the aforementioned method, and plotted a standard curve and half-maximal effect concentration (EC50) based on the BRET ratio. 50 Nonlinear fitting curve.
[0105] The results are as follows Figure 7 As shown.
[0106] It was observed that by incubating the aforementioned biosensor and 10 nM plasmin at room temperature for different times and then collecting and detecting fluorescence signals, the dynamic range of the BRET ratio changed significantly when the incubation time reached 10 min. Within the 10-30 min range, the BRET ratio tended to stabilize. However, after the incubation time exceeded 45 min, the dynamic range of the BRET ratio began to show a downward trend, indicating that the detection dynamic range gradually increases with prolonged incubation time. A rapid detection time of at least ≥10 min is required to achieve a sufficient BRET dynamic range for effective detection of plasmin. At an incubation time of 30 min, the maximum dynamic range for plasmin detection was 440.7 ± 14.3%, which is approximately 6.3 times higher than the existing BRET6 detection technology (maximum dynamic range approximately 70%).
[0107] The resulting working curves for the biosensor at standard concentrations of plasmin are as follows:
[0108] Y = -0.006310X + 2.065;
[0109] Where Y is the BRET ratio, and X is the standard concentration of plasminogen activator. 2 The value was 0.9712. Using the 3σ standard to evaluate the above working curves, the detection range of the biosensor was found to be 10-100 pM, and the limit of detection (LOD) was 0.732 pM. This LOD is 99.09% lower than the existing BRET6 detection technology (0.732 pM vs 0.08 nM). The half-maximal effect concentration (EC50) was obtained by nonlinearly fitting the plasmin concentration and its response value using GraphPad Prism 9.0 software. 50 The apparent affinity constant (K) is 0.241 nM. d,app The value is 0.225 nM, where EC 50Compared to the existing BRET6 detection technology, the detection efficiency is reduced by 49.8% (0.241 nM vs 0.48 nM), and the affinity constant is in the nM range. This indicates that the affinity and detection sensitivity of this sensor are significantly improved compared to the existing technology, thus demonstrating that the biosensor in the embodiments of the present invention is more suitable for the accurate determination of plasminogen activator.
[0110] Further prepare human plasma samples containing 0.1% plasmin and perform detection using the above-described detection method.
[0111] The results are as follows Figure 8 As shown.
[0112] It can be observed that the obtained working curve of the biosensor for the standard concentration of plasmin is as follows:
[0113] Y = -0.009663X + 2.240;
[0114] Where Y is the BRET ratio, and X is the standard concentration of plasminogen activator. 2 The value was 0.9916. Using the 3σ standard to evaluate the above working curves, the biosensor's detection range was found to be 10-100 pM, with a limit of detection (LOD) of 0.644 pM. This LOD was 13.7% lower than the detection value with PBS buffer background (0.644 pM vs 0.732 pM). The half-maximal effect concentration (EC50) was obtained by nonlinearly fitting the plasmin concentration and its response value using GraphPadPrism 9.0 software. 50 The apparent affinity constant (K) is 0.374 nM. d,app The molecular weight (M) was 0.273 nM, and there was no significant change between the two, indicating that the biosensor in the above embodiments did not show significant changes in binding affinity to the protease in different buffer systems or backgrounds. However, the dynamic range (DR) was 1.2 times higher in 0.1% plasma than in PBS buffer (515.8 ± 22.0% vs 440.7 ± 14.3%), but the apparent affinity (K) was lower. d,app The size increased by 1.2 times, so the detection sensitivity only decreased by 13.7%.
[0115] Application of the above-mentioned biosensors in the screening or efficacy evaluation of protease inhibitors or related targeted drugs
[0116] To fully demonstrate the feasibility of the above-mentioned biosensor in the screening or efficacy evaluation of protease inhibitors or related drugs, the inventors tested it using two different known plasminogen activators as test subjects.
[0117] In the following embodiments, the biosensors used are all the biosensors in Example 1.
[0118] (1) Evaluation of the inhibitory efficiency of biosensors on the endogenous inhibitor anti-plasmin:
[0119] The total reaction volume was set to 100 μL. A final concentration of 10 nM plasmin was added, along with a final concentration of 1 nM biosensor and different concentrations (0, 1, 4, 8, 10, 15, and 20 nM) of the plasmin endogenous inhibitor anti-plasmin. After incubation at room temperature with shaking for 30 min, 25 μM of enterolucin 400a substrate was rapidly added, with the remainder made up using PBS phosphate buffer (pH 7.4). Fluorescence signals were detected using a multi-mode microplate reader after the addition of enterolucin 400a substrate. BRET energy transfer efficiency was evaluated using a ratio method, calculated as the ratio of the fluorescence intensity of the receptor fluorescent protein at 500-550 nm to the fluorescence intensity of the donor luciferase at 415-465 nm. The plasmin concentration and its inhibition rate were nonlinearly fitted using GraphPad Prism 9.0 software. The dynamics were verified using Fortebio octet biofilm layer optical interferometry (BLI).
[0120] The results are as follows Figure 9 As shown.
[0121] It can be observed that the half-maximal inhibitory concentration (IC50) measured using the biosensor in this embodiment of the invention is 10.83 nM. BLI validation results confirm that when the anti-plasmin concentration is higher than 10 nM, the activity of plasmin can be essentially inhibited. At this point, the biosensor and plasmin are in an unbound state. However, as the inhibitor concentration decreases, the inhibitory effect of plasmin weakens, the plasmin's ability to cleave and recognize the biosensor recovers, and the dissociation rate of the biosensor after cleavage gradually increases. These results indicate that the biosensor in this embodiment of the invention can be effectively used to test the inhibitory effect of anti-plasmin on plasmin, and the detection results are accurate.
[0122] (2) Evaluation of the inhibitory efficiency of biosensors on the peptide inhibitor aprotinin:
[0123] The experimental method is the same as (1), wherein the test concentration of aprotinin is set to 0, 1, 4, 8, 10, 15 and 20 nM.
[0124] The results are as follows Figure 10 As shown.
[0125] It can be observed that the half-maximal inhibitory concentration (IC50) measured using the biosensor in this embodiment of the invention is 19.96 nM. BLI validation results confirm that with increasing aprotinin concentration, plasmin activity is significantly inhibited, and the plasmin's ability to recognize the cleavage of the biosensor weakens, leading to a gradual slowdown in the dissociation rate of the biosensor after cleavage. These results demonstrate that the biosensor in this embodiment of the invention can be effectively used to test the inhibitory effect of aprotinin on plasmin, and the detection results are accurate.
[0126] (3) Evaluation of the inhibitory efficiency of the biosensor on leupeptin:
[0127] The experimental method is the same as (1), where leupeptin is available in 0 nM, 1 nM, 1 μM and 5 μM.
[0128] The results are as follows Figure 11 As shown.
[0129] It can be observed that the half-maximal inhibitory concentration (IC50) measured using the biosensor in this embodiment of the invention is 3.941 μM. BLI validation results confirm that with increasing leupeptin concentration, plasmin activity is significantly inhibited, and the plasmin's ability to recognize the cleavage of the biosensor weakens, leading to a gradual slowdown in the dissociation rate of the biosensor after cleavage. These results demonstrate that the biosensor in this embodiment of the invention can be effectively used to test the inhibitory effect of leupeptin on plasmin, and the detection results are accurate.
[0130] (4) The application effect of biosensors in the screening of protease inhibitors:
[0131] In this embodiment, the normal drug screening is simulated by competitively inhibiting plasmin activity using the endogenous inhibitor anti-plasmin and the peptide inhibitor aprotinin.
[0132] The methods for inhibiting plasmin activity by endogenous inhibitors anti-plasmin, peptide inhibitors aprotinin and leupeptin are the same as those for (1) to (3).
[0133] The results showed significant differences in the inhibitory activities of the endogenous inhibitor anti-plasmin, the peptide inhibitor aprotinin, and the peptide inhibitor leupeptin against 10 nM plasmin. Specifically, the IC50 of the endogenous inhibitor anti-plasmin was 10.83 nM, the IC50 of the peptide inhibitor aprotinin was 19.96 nM, and the IC50 of the peptide inhibitor leupeptin was 3.941 μM. This means that to inhibit the same concentration of plasmin, the amount of aprotinin required was 1.8 times higher than that of the endogenous inhibitor anti-plasmin, and the amount of leupeptin required was 363.9 times higher than that of the endogenous inhibitor anti-plasmin. This indicates that the endogenous inhibitor anti-plasmin is more effective than aprotinin, especially showing an order-of-magnitude improvement over leupeptin. Therefore, it can be demonstrated that it is feasible to use the biosensor in the above embodiments to efficiently, rapidly screen for inhibitors or drugs targeting plasminogen lysates, and this method is also suitable for screening other types of inhibitors.
[0134] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.
Claims
1. A biosensor, characterized by, The biosensor consists of a bioluminescent resonance energy transfer donor, a protease-recognized cleaved short peptide, and a bioluminescent resonance energy transfer acceptor. The protease recognizes and cleaves short peptides, which are then linked to a bioluminescent resonance energy transfer donor and a bioluminescent resonance energy transfer acceptor in the biosensor via two linker fragments, respectively. The linker fragment is shown in SEQ ID NO: 3; The protease recognizes and cleaves short peptides as shown in SEQ ID NO:4; The bioluminescent resonance energy transfer donor is NanoLuc luciferase; The bioluminescent resonance energy transfer receptor is mNeonGreen green fluorescent protein.
2. The biosensor of claim 1, wherein, The protease recognizes and cleaves short peptides specifically bound to proteases, and is then cleaved by the protease.
3. The biosensor of claim 2, wherein, The protease is a plasminogen activator.
4. A method for preparing a biosensor, comprising the following steps: (1) The functional units of the biosensor according to any one of claims 1 to 3 are recombined and linked in the expression vector; the functional units include a bioluminescent resonance energy transfer donor, a linker fragment, a bioluminescent resonance energy transfer receptor, and a protease-recognized cleavage short peptide; (2) Screen positive clones, extract plasmids, transform them into competent cells and induce protein expression; (3) Break the cells and extract the crude protein, which is the biosensor.
5. The use of the biosensor according to any one of claims 1 to 3 in any one of the following (1) to (3); (1) Preparation of products for qualitative or quantitative detection of proteases; (2) Preparation of screening products for protease inhibitors or targeting substances; (3) Prepare products for quantitative comparison or effect evaluation of the activity of protease inhibitors or targeting substances; wherein The protease is a plasminogen activator.
Citation Information
Patent Citations
Extracellular matrix MMP13 (metalloproteinase-13) detection BRET (bioluminescence resonance energy transfer) probe, gene, expression vector and construction method
CN104788569A
Protease sensor molecules
CN110494569A
